Ablynx to receive milestone for bi-specific nanobody in oncology

01-Feb-2016 - Belgium

Ablynx announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study is to evaluate the safety profile and dosing schedule for this Nanobody.

The anti-VEGF/Ang2 Nanobody was discovered and developed as part of the Strategic Alliance between both parties, signed in September 2007. This Nanobody blocks both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), important proteins which are involved in the formation of new blood vessels from pre-existing vessels (angiogenesis), a vital mechanism in the growth of tumours.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances